Introduction
Melanoma differentiation-associated gene 5 (MDA-5) plays a role in regulating the innate immune system response against viral infections and in activating the expression of type I interferons [1] . The association of MDA-5 antibodies with connective tissue disease (CTD) has been studied mainly in patients with inflammatory myopathies. These patients were found to have a distinct clinical phenotype of no or mild muscle disease, mucocutaneous ulcerations, tender palmar papules, synovitis, and increased incidence of interstitial lung disease (ILD) [2] [3] . A descriptive US cohort of 160 dermatomyositis (DM) patients found that many with positive MDA-5 antibodies were initially misclassified as having either rheumatoid arthritis or as having an overlap syndrome due the presence of synovitis, Raynaud' s, myositis, and/or ILD [2] . Additionally, a portion of the cohort presented with features indistinguishable from antisynthetase syndrome in the absence of tRNA synthetases [2] . These findings support the idea that there is a broad clinical spectrum of anti-MDA-5 associated CTD. We describe an 11-year old boy whose clinical find-Year 2015 | Volume:X | Issue:X | XX Annals of Paediatric Rheumatology ings consisted of inflammatory arthritis, fasciitis, elevated ferritin, and elevated liver function tests (LFTs). He was found to have positive MDA-5 antibodies. This is the first reported case of fasciitis in anti-MDA-5 associated CTD.
Case Report Our patient is an 11-year-old male whose symptoms started in May 2014 when he presented to his general pediatrician with several days history of low grade fevers, fatigue, malaise, and left hip pain. The patient was managed symptomatically at that time for presumptive viral illness. The fever and fatigue resolved but he continued to experience intermittent hip pain. Approximately four weeks later, the patient was admitted to the hospital with a two day history of increasing left hip and thigh pain, low-grade fevers, and fatigue. Laboratory studies revealed normal complete blood counts, normal serum creatinine, elevated LFTs home on this regimen. At the end of July 2014, his fevers completely resolved but fatigue and left hip and thigh pain persisted. In addition, he also developed widespread arthralgia involving both hands and feet with prolonged morning stiffness. His examination demonstrated swelling and tenderness of all interphalangeal, metacarpophalangeal and both wrist joints, limited range of motion of knees and hips secondary to pain, and tenderness over metatarsophalangeal and ankle joints. In addition, he had severe pain and tenderness in both thighs which was exacerbated by active and passive knee flexion. MRI of his thighs showed increased enhancement in the perimysial fascia of bilateral hamstrings and quadriceps without evidence of muscle edema or myositis [ figure 1 ]. Formal neuromuscular examination revealed no evidence of neurologic deficit or clinical myopathy. MRI of the right wrist showed diffuse tenosynovitis and fasciitis. Further investigation also revealed positive antinuclear antibody (ANA) test (1:80 speckled pattern), elevated ferritin (876 ng/ml), elevated D-dimer levels (410 ng/ml) and elevated triglycerides (372 mg/dl). The working diagnosis at this point was connective tissue disease (CTD) with possible associated macrophage activation syndrome (elevated ferritin, LFTs, D-dimer levels, and triglycerides).
The patient was started on prednisone 20mg twice daily with mild symptomatic improvement but worsening in LFTs and no change in LDH, aldolase and ferritin levels [table 1]. Anakinra was added and prednisone dose decreased to 20mg once daily; this resulted in resolution of his joint and thigh pains, and improvement in morning stiffness. Ferritin levels started trending down and normalized 6 weeks later. Repeat thigh MRI in November 2014 at three months showed evidence of worsening fasciitis now extending to multiple bilateral thigh muscles without evidence of myositis. Left thigh muscle biopsy showed normal muscle fibers with no evidence of fiber degeneration, regeneration, inflammation, or fibrosis and with no significant histologic abnormalities. Liver biopsy showed non-specific findings of mild macro-vesicular steatosis with minimal portal and lobular inflammation. Myositis specific antibody testing revealed moderately positive MDA-5 (melanoma differentiation-associated protein 5) antibodies. Anakinra was discontinued and switched to mycophenolate mofetil with monthly intravenous immunoglobulin and monthly pulse dose methylprednisolone infusions. Repeat MRI of the thigh two months later showed persistent fasciitis with partial improvement in the quadriceps but worsening in the hamstring fascia. Pulmonary function tests (PFTs) and high resolution computed tomography (HRCT) of the chest revealed no evidence of pulmonary involvement.
Discussion Myositis specific antibodies (MSA) and myositis associated antibodies (MAA) are estimated to be present in 50-80% of patients with inflammatory myopathies [7] [8] and their presence can be associated with distinct clinical phenotypes [4] .
The MDA-5 gene encodes a cytoplasmic RNA helicase that is part of the innate immune response to viral infections [1] [5] . MDA5 acts as a sensor for double-strand RNAs of viruses such as coxsackievirus, which have been implicated in the development of JDM, and induces type I interferon, a pro-inflammatory cytokine and potent stimulator of B, T, and natural killer cells [6] . The presence of this autoantibody in patients with inflammatory myopathies is believed to be associated with a distinct phenotype lacking or with mild myositis, skin ulcerations, tender palmar papules, synovitis, and a high incidence of ILD [2] [3] . The few clinical studies that explored the clinical significance of anti-MDA-5 antibodies focus on patients with inflammatory myositis. One recent US study of 160 DM patients showed that anti-MDA-5 associated disease can have a broad range of manifestations [2] . In fact, anti-MDA-5 positive patients may initially be labeled as having an overlap disorder due to the presence of significant synovitis along with other features like Raynaud' s phenomenon, myositis and ILD [2] ; in addition, some patients present with defining features of the antisynthetase syndrome in the absence of tRNA synthetase antibodies [2] . This study and other previous studies of anti-MDA-5 associated disease only included patients with DM or other types of inflammatory myopathies. The extent to which anti MDA-5 associated disease extends beyond the phenotype for classically defined DM is currently unknown.
Our patient did not meet the clinical criteria for diagnosis of JDM as he had no evidence of myositis and lacked characteristic skin manifestations like Heliotrope and Gottron' s rash-es. Absence of myopathy or myositis was evidenced by normal CPK, normal neuromuscular examination, and normal muscle biopsy, as well as lack of myositis on MR imaging. On the other hand, he had a constellation of symptoms strongly suggestive of an underlying CTD, including-symmetrical inflammatory polyarthritis, fasciitis, elevated LFTs and ferritin levels. Anti-MDA-5 antibody measurement in this case was a valuable tool in characterizing his disease as a connective tissue disease with potential similarity to amyopathic JDM. This information helped to guide the treatment and follow up plans for this patient. This case illustrates the broad spectrum of anti-MDA-5 associated disease, which in this case was characterized by elevated ferritin, fasciitis and arthritis with no evidence of myositis or myopathy. The presence of significant fasciitis in this case is unique as this finding has not been reported before in anti-MDA-5 associated CTD. More studies are needed to better understand the different clinical manifestations of anti-MDA-5 associated disease.
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